Does Blue Cross Blue Shield of Texas Cover Jardiance?

What Is Jardiance and Why Does Coverage Matter?

Jardiance (empagliflozin) is an FDA-approved sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and Eli Lilly. The FDA first approved empagliflozin in August 2014 for glycemic control in adults with type 2 diabetes, and the agency has since expanded that label to include adults with heart failure with reduced ejection fraction (HFrEF) in 2021, heart failure with preserved ejection fraction (HFpEF) in 2022, and chronic kidney disease (CKD) in 2023 [1].

What Jardiance Actually Does

Empagliflozin blocks SGLT2 transporters in the proximal renal tubule, forcing the kidneys to excrete roughly 70 to 90 grams of glucose per day in the urine rather than reabsorbing it [2]. The result is a modest but sustained reduction in HbA1c (approximately 0.6 to 0.8 percentage points at 10 mg and 0.7 to 0.9 percentage points at 25 mg in key trials), plus clinically meaningful reductions in systolic blood pressure (roughly 4 mmHg) and body weight (roughly 2 to 3 kg) [3].

Why the Cardiovascular and Kidney Data Changed Prescribing

The EMPA-REG OUTCOME trial (N=7,020, median follow-up 3.1 years) showed that empagliflozin reduced the risk of cardiovascular death by 38% relative to placebo (hazard ratio 0.62; 95% CI 0.49 to 0.77; P<0.001) in adults with type 2 diabetes and established cardiovascular disease [4]. The EMPEROR-Reduced trial (N=3,730) then demonstrated that empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% versus placebo in patients with HFrEF (hazard ratio 0.75; 95% CI 0.65 to 0.86; P<0.001), including patients without diabetes [5].

These outcomes shifted major guidelines. The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen, independent of HbA1c" [6]. That clinical urgency makes insurance access a practical patient problem, not merely a billing question.

How BCBS Texas Formularies Are Structured

Blue Cross Blue Shield of Texas operates under the Health Care Service Corporation (HCSC) umbrella and administers dozens of distinct formularies across its commercial, marketplace (ACA), Medicare Advantage, and Federal Employee Program (FEP) lines of business. No single answer covers every member uniformly.

Tier Placement for Empagliflozin

On the majority of BCBS Texas commercial formularies reviewed in 2024 and early 2025, Jardiance lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A small number of high-deductible health plans place it on Tier 5 (specialty). Tier placement determines your copay or coinsurance before and after the deductible. Typical cost-sharing structures look like this:

• Tier 3 (preferred brand): $60, $120 copay per 30-day fill after deductible
• Tier 4 (non-preferred brand): $90, $200 copay or 30 to 40% coinsurance after deductible
• Tier 5 (specialty): 20 to 40% coinsurance, sometimes with a monthly cap

The only way to confirm your plan's exact tier is to log in to the BCBS Texas member portal (bcbstx.com), manage to "Prescription Benefits," and search for empagliflozin by its generic name. The portal reflects your specific group contract, not a generic plan average.

Medicare Advantage and Part D Plans

Medicare Advantage plans sold by BCBS Texas (marketed as Blue Advantage) follow CMS-regulated formulary rules. Under Medicare Part D, SGLT2 inhibitors must be covered if they appear on your plan's formulary, but the tier and step-therapy requirements vary by contract. In 2024, most BCBS Texas Blue Advantage plans listed Jardiance on Tier 4 or Tier 5 with prior authorization required. The CMS formulary search tool at medicare.gov allows beneficiaries to compare costs across plan options before open enrollment closes.

The Eli Lilly copay savings card is explicitly not valid for Medicare, Medicaid, CHIP, or any other government-funded plan. Patients on these programs should ask their prescriber about the Lilly Insulin Value Program or patient assistance through the Lilly Cares Foundation [7].

Prior Authorization: What BCBS Texas Requires

Prior authorization (PA) is required for Jardiance on most BCBS Texas commercial plans. The PA criteria are not published in a single publicly accessible document, but they generally mirror the clinical criteria endorsed by the American Diabetes Association [6] and typically include the following elements:

Diagnosis Requirements

The prescriber must document one or more of the following:

1. Type 2 diabetes mellitus with an HbA1c above 7.0% (or the plan's specified threshold, sometimes 8.0%)
2. Heart failure (HFrEF or HFpEF) regardless of diabetes status, following FDA label expansion
3. Chronic kidney disease (CKD stages 2 to 4 with albuminuria) per the CREDENCE and DAPA-CKD trial evidence base [8]

Step Therapy Requirements

Most BCBS Texas commercial plans require documented trial and inadequate response to at least one prior agent, which in practice means:

• Metformin for at least 90 days at a therapeutic dose (typically 1,000 to 2,000 mg/day)
• Sometimes one additional oral agent (sulfonylurea, DPP-4 inhibitor, or another SGLT2 inhibitor at a lower formulary tier)

Step therapy exceptions can be requested when step therapy would be medically contraindicated. Metformin is contraindicated or poorly tolerated in patients with an eGFR <30 mL/min/1.73m² or significant GI intolerance, and a prescriber attestation to that effect typically satisfies the exception criterion.

How to Submit the PA

The prescriber or their office staff submits the PA through the BCBS Texas provider portal, CoverMyMeds, or by fax using the prior authorization request form. BCBS Texas is required by Texas state law (Texas Insurance Code §843.348) to issue an initial determination within three business days for routine requests and 24 hours for urgent requests. If approved, PA is typically valid for 12 months, after which renewal is required.

What to Do If BCBS Texas Denies Your Jardiance Claim

Denials happen. They are not always final.

Step 1: Read the Denial Letter Carefully

The Explanation of Benefits (EOB) or denial letter will state the specific reason: formulary exclusion, step therapy not met, PA not submitted, or medical necessity not established. Each reason has a different appeal path.

Step 2: File an Internal Appeal

Texas law requires BCBS Texas to accept and process internal appeals. File within 180 days of the denial date. Include a letter of medical necessity from the prescribing physician that references the relevant clinical trial data (EMPA-REG OUTCOME [4], EMPEROR-Reduced [5], or CREDENCE [8]) and the ADA Standards of Care guideline language [6]. Specific evidence improves appeal success rates.

Step 3: Request an Independent External Review

If the internal appeal is denied, Texas Insurance Code §1259.052 gives you the right to an independent external review by an Independent Review Organization (IRO). The Texas Department of Insurance oversees this process. An IRO decision favorable to the patient is binding on the insurer.

Step 4: Consider Therapeutic Alternatives While Appealing

While the appeal is pending, ask your prescriber whether dapagliflozin (Farxiga) or canagliflozin (Invokana) sits on a lower formulary tier under your specific BCBS Texas plan. Both are SGLT2 inhibitors with their own FDA-approved cardiovascular and renal indications and with head-to-head cardiovascular outcome trial data [9]. Switching agents is not always clinically equivalent, but it may provide continuity of therapy during the PA process.

Copay Assistance and Patient Savings Programs

Eli Lilly Jardiance Savings Card

Eli Lilly offers a commercial copay savings card for Jardiance. Eligible commercially insured patients (those not on Medicare, Medicaid, or other government programs) may pay as little as $10 per month, with Lilly covering up to $150 per prescription fill. Enrollment is available at jardiance.com. The savings card cannot be used at certain pharmacies that do not accept third-party discount cards, so confirm eligibility at the point of dispensing.

Lilly Cares Foundation Patient Assistance Program

Uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level) may receive Jardiance at no cost through the Lilly Cares Foundation. Applications are submitted at lillycares.com or through the prescribing physician's office [7].

GoodRx and Pharmacy Discount Programs

GoodRx prices for Jardiance 10 mg (30 tablets) range from approximately $580 to $650 depending on pharmacy location as of January 2025. Using a GoodRx coupon at a participating pharmacy bypasses insurance entirely but means the cost does not apply to your deductible. For patients who have already met their annual deductible, using insurance is generally preferable. For those early in a high-deductible plan year, a GoodRx coupon may lower the immediate out-of-pocket cost.

Clinical Context: Why Prescribers Fight for Coverage

The clinical evidence supporting Jardiance extends well beyond blood sugar reduction. The EMPEROR-Preserved trial (N=5,988) showed that empagliflozin reduced the primary composite of cardiovascular death or hospitalization for worsening heart failure by 21% versus placebo (hazard ratio 0.79; 95% CI 0.69 to 0.90; P<0.001) in patients with HFpEF, a condition for which very few treatments had previously demonstrated outcome benefit [10].

The CREDENCE trial (N=4,401), which tested canagliflozin rather than empagliflozin but is directly relevant to the CKD indication class, demonstrated a 30% reduction in the relative risk of the primary composite endpoint (end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death) versus placebo (hazard ratio 0.70; 95% CI 0.59 to 0.82; P<0.001) [8]. The EMPA-KIDNEY trial subsequently confirmed empagliflozin's specific renal benefits (N=6,609; 28% relative risk reduction in the composite of kidney disease progression or cardiovascular death; P<0.001) [11].

"SGLT2 inhibitors have moved from being glucose-lowering drugs to being cardiorenal-protective drugs," said Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine and one of the EMPA-REG OUTCOME principal investigators, in commentary published in the New England Journal of Medicine [4].

These outcomes are precisely why the American Diabetes Association's 2024 Standards of Care prioritize SGLT2 inhibitors with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease, regardless of HbA1c [6]. The guideline is explicit: cardiorenal protection is the primary reason to prescribe, not glycemic control alone.

Verifying Your Own BCBS Texas Coverage: A Step-by-Step Checklist

Because coverage varies by plan and contract year, the following steps give you the most accurate picture of your specific situation:

1. Log in to bcbstx.com and manage to "My Plan" then "Prescription Benefits." Search for "empagliflozin" by generic name.
2. Note the tier, copay/coinsurance, and any PA or step-therapy flag listed for your plan year.
3. Call the member services number on the back of your insurance card and ask specifically: "Is a prior authorization required for empagliflozin 10 mg? What are the medical necessity criteria?"
4. Ask your prescriber's office to run a coverage check through CoverMyMeds or the BCBS Texas provider portal before submitting a prescription. Early PA submission prevents a gap in therapy.
5. Enroll in the Lilly savings card at jardiance.com before your first fill if you are commercially insured. Enrollment takes under five minutes and the card is generally active immediately.
6. Check your deductible status through the member portal before deciding between using insurance and a GoodRx coupon. Once your deductible is met, insurance is almost always cheaper.

Frequently Asked Questions